Relay Therapeutics (RLAY) Income from Continuing Operations (2019 - 2026)
Relay Therapeutics' (RLAY) quarterly Income from Continuing Operations came in at 79127000.0 in Q1 2026, down 1.49% year-on-year from 80322038.47 in Q1 2025, and down 125.53% on a QoQ basis from 35085000.0 in Q4 2025.
Relay Therapeutics (RLAY) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 8 years of Income from Continuing Operations data on file, last reported at 79127000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 1.49% year-over-year to 79127000.0 in Q1 2026; TTM through Mar 2026 was 262415000.0, a 64.77% increase from a year earlier, with the FY2025 full-year figure at 756220000.0, up 1.75% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 79127000.0, down from 35085000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for RLAY reached as high as 35085000.0 in Q4 2025 and fell as low as 484867000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 105837588.24 across 5 years, with a median of 82708000.0 in 2024.
- Across the five-year window, Income from Continuing Operations plunged 443.15% in 2024 and surged 92.76% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 75058000.0 in 2022, then dropped by 18.93% to 89269000.0 in 2023, then plunged by 443.15% to 484867000.0 in 2024, then jumped by 92.76% to 35085000.0 in 2025, then sank by 125.53% to 79127000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 79127000.0 in Q1 2026, 35085000.0 in Q4 2025, and 74223000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Relay Therapeutics | 3.31 Bn | 3.31 Bn | - | -79.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79.13 Mn |
| Dec 31, 2025 | -35.09 Mn |
| Sep 30, 2025 | -74.22 Mn |
| Jun 30, 2025 | -73.98 Mn |
| Mar 31, 2025 | -77.97 Mn |
| Dec 31, 2024 | -484.87 Mn |
| Sep 30, 2024 | -88.39 Mn |
| Jun 30, 2024 | -93.56 Mn |
| Mar 31, 2024 | -82.71 Mn |
| Dec 31, 2023 | -89.27 Mn |
| Sep 30, 2023 | -74.27 Mn |
| Jun 30, 2023 | -112.41 Mn |
| Mar 31, 2023 | -100.57 Mn |
| Dec 31, 2022 | -75.06 Mn |
| Sep 30, 2022 | -85.28 Mn |
| Jun 30, 2022 | -92.41 Mn |
| Mar 31, 2022 | -80.07 Mn |
| Dec 31, 2021 | -73.44 Mn |
| Sep 30, 2021 | -61.92 Mn |
| Jun 30, 2021 | -193.74 Mn |